Grifols, S.A. (GRFS)Healthcare | Drug Manufacturers - General | Barcelona, Spain | NasdaqGS
8.75 USD
+0.15
(1.744%)
⇧
(April 17, 2026, 4 p.m.
EDT)
After hours: 8.75 Short-term: ★★☆☆☆ | Long-term: ★★★☆☆ | Dividends: ★★★☆☆ |
Hot Take | April 11, 2026, 3:49 p.m. EDT
GRFS appears to be in a consolidation phase with recent price action hovering around the 8.00 mark. The stock has shown some volatility but remains within its 52-week range. While the dividend yield is attractive, the low payout ratio and recent dip in price suggest caution. The options activity hints at potential for short-term swings, but the forecasting model shows minimal directional movement, making it a neutral to slightly bearish short-term opportunity. For long-term investors, the fundamentals are solid, but the high debt-to-equity ratio and recent earnings growth should be monitored. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.084926 |
| AutoETS | 0.085938 |
| AutoARIMA | 0.085938 |
| AutoTheta | 0.089764 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 41% |
| H-stat | 42.07 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.201 |
| Excess Kurtosis | -1.30 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Ex Dividend Date | 2025-08-11 |
| Last Dividend Date | 2025-08-11 |
| Debt to Equity Ratio | 126.832 |
| Revenue per Share | 5.528 |
| Market Cap | 7,186,585,088 |
| Trailing P/E | 13.67 |
| Forward P/E | 6.01 |
| Beta | 1.21 |
| Profit Margins | 5.34% |
| Website | https://www.grifols.com |
As of April 11, 2026, 3:49 p.m. EDT: Options speculators are showing mixed signals. The ATM strikes for calls and puts are heavily positioned, indicating potential for volatility around the current price. However, the overall volume and open interest suggest limited conviction in either direction. The elevated IV on certain expirations indicates uncertainty or anticipation of significant price movements, but the lack of clear directional bias makes it challenging to determine a strong short-term trend.
| Last Yield | 1yr Yield | 3yr Avg | 5yr Avg |
|---|---|---|---|
| 1.63% | 1.63% | 0.54% | 0.88% |
| Date | Dividend | Yield % |
|---|---|---|
| 2025-08-12 | 0.1730 | 1.632075 |
| 2021-06-03 | 0.4560 | 2.765905 |
| 2020-10-30 | 0.2010 | 1.235676 |
| 2019-12-02 | 0.2200 | 1.026147 |
| 2019-06-07 | 0.1740 | 0.976378 |
| 2018-11-30 | 0.2280 | 1.244919 |
| 2018-06-01 | 0.2510 | 1.244301 |
| 2017-12-01 | 0.2120 | 1.051693 |
| 2017-05-30 | 0.1630 | 0.857552 |
| 2016-12-05 | 0.1910 | 1.450576 |
| 2016-06-02 | 0.1590 | 1.071184 |
| 2015-12-10 | 0.1850 | 1.284067 |
| 2015-06-08 | 0.1675 | 1.271919 |
| 2014-12-04 | 0.1565 | 1.059242 |
| 2014-06-05 | 0.1435 | 0.794115 |
| 2013-06-05 | 0.1295 | 1.149294 |
| 2013-05-29 | 0.0065 | 0.057809 |
| Attribute | Value |
|---|---|
| 52 Week Change | 0.2268188 |
| Address1 | Parque Empresarial Can Sant Joan |
| Address2 | Avinguda de la Generalitat, 152-158 Sant Cugat del Valles |
| All Time High | 25.73 |
| All Time Low | 4.542857 |
| Ask | 8.77 |
| Ask Size | 2 |
| Average Analyst Rating | 2.0 - Buy |
| Average Daily Volume10 Day | 584,330 |
| Average Daily Volume3 Month | 664,572 |
| Average Volume | 664,572 |
| Average Volume10Days | 584,330 |
| Beta | 1.205 |
| Bid | 8.7 |
| Bid Size | 2 |
| Book Value | 4.5688143 |
| City | Barcelona |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | Spain |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 8.75 |
| Current Ratio | 2.513 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 8.83 |
| Day Low | 8.58 |
| Debt To Equity | 126.832 |
| Dividend Date | 1,755,648,000 |
| Dividend Rate | 0.18 |
| Dividend Yield | 2.04 |
| Earnings Call Timestamp End | 1,772,139,600 |
| Earnings Call Timestamp Start | 1,772,139,600 |
| Earnings Growth | 0.435 |
| Earnings Quarterly Growth | 0.423 |
| Earnings Timestamp | 1,772,139,600 |
| Earnings Timestamp End | 1,772,139,600 |
| Earnings Timestamp Start | 1,772,139,600 |
| Ebitda | 1,697,230,976 |
| Ebitda Margins | 0.22558 |
| Enterprise To Ebitda | 10.064 |
| Enterprise To Revenue | 2.27 |
| Enterprise Value | 17,081,033,728 |
| Eps Current Year | 1.16702 |
| Eps Forward | 1.45656 |
| Eps Trailing Twelve Months | 0.64 |
| Esg Populated | 0 |
| Ex Dividend Date | 1,754,956,800 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fax | 34 938 00 80 00 |
| Fifty Day Average | 8.5424 |
| Fifty Day Average Change | 0.20759964 |
| Fifty Day Average Change Percent | 0.024302261 |
| Fifty Two Week Change Percent | 22.68188 |
| Fifty Two Week High | 11.14 |
| Fifty Two Week High Change | -2.3900003 |
| Fifty Two Week High Change Percent | -0.21454221 |
| Fifty Two Week Low | 6.86 |
| Fifty Two Week Low Change | 1.8899999 |
| Fifty Two Week Low Change Percent | 0.2755102 |
| Fifty Two Week Range | 6.86 - 11.14 |
| Financial Currency | EUR |
| First Trade Date Milliseconds | 1,307,021,400,000 |
| Five Year Avg Dividend Yield | 2.4 |
| Float Shares | 417,315,170 |
| Forward Eps | 1.45656 |
| Forward P E | 6.0073047 |
| Free Cashflow | 1,025,019,392 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 25,258 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.38799998 |
| Gross Profits | 2,919,322,880 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.0 |
| Held Percent Institutions | 0.574 |
| Implied Shares Outstanding | 821,324,025 |
| Industry | Drug Manufacturers - General |
| Industry Disp | Drug Manufacturers - General |
| Industry Key | drug-manufacturers-general |
| Is Earnings Date Estimate | 0 |
| Language | en-US |
| Last Dividend Date | 1,754,956,800 |
| Last Dividend Value | 0.173 |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,451,865,600 |
| Last Split Factor | 2:1 |
| Long Business Summary | Grifols, S.A., together with its subsidiaries, engages in the research, development, production, and marketing of plasma-derived medicines in the United States, Canada, Spain, Europe, and internationally. It operates through four segments: Biopharma, Diagnostic, Bio Supplies, and Others. The company offers various hemoderivatives from human plasma for immunology, infectious diseases, hepatology, intensive care, pulmonology, hematology, and neurology treatment areas; and markets diagnostic testing equipment, reagents, and other equipment, as well as provides transfusion medicine, clinical diagnostics, and testing services. It also offers biological products, including albumin, albumin-derived products, immunoglobulins, thrombin, other proteins, and intermediate plasma products to pharma and biotech companies for biopharma use; and whole blood, blood components, processed plasma, and clinical samples to life-science research and in-vitro diagnostic companies for diagnostic use. In addition, the company provides healthcare solutions for hospitals, such as intravenous solutions to maintain or restore fluids and electrolyte balance in patients; high-tech solutions to automate hospital processes; clinical nutrition to deliver nutrition and medication; and medical devices comprising instrumentation and disposable materials for various hospital services, which include interventional neuroradiology, hemodynamics, urology, anesthesiology and cardiovascular surgery, as well as manufacturing services to third parties and research activities. Further, it is involved in engineering services; packaging, labelling, storage, distribution, manufacturing, and development of pharmaceutical products; import, export, and commercialization activities; travel agency services; reinsurance of insurance policies; support services; law business; and consultation, administration, and financing services. The company was founded in 1909 and is headquartered in Barcelona, Spain. |
| Long Name | Grifols, S.A. |
| Market | us_market |
| Market Cap | 7,186,585,088 |
| Market State | POSTPOST |
| Max Age | 86,400 |
| Message Board Id | finmb_734865 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | 402,000,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 6,950,822,861 |
| Number Of Analyst Opinions | 2 |
| Open | 8.8 |
| Operating Cashflow | 1,047,000,000 |
| Operating Margins | 0.1753 |
| Payout Ratio | 0.275 |
| Peg Ratio | 0.1938 |
| Phone | 34 935 71 22 00 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 8.75 |
| Post Market Time | 1,776,456,268 |
| Previous Close | 8.6 |
| Price Eps Current Year | 7.4977293 |
| Price Hint | 2 |
| Price To Book | 1.9151577 |
| Price To Sales Trailing12 Months | 0.9551549 |
| Profit Margins | 0.05343 |
| Quick Ratio | 0.839 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | buy |
| Recommendation Mean | 2.0 |
| Region | US |
| Regular Market Change | 0.15 |
| Regular Market Change Percent | 1.74418 |
| Regular Market Day High | 8.83 |
| Regular Market Day Low | 8.58 |
| Regular Market Day Range | 8.58 - 8.83 |
| Regular Market Open | 8.8 |
| Regular Market Previous Close | 8.6 |
| Regular Market Price | 8.75 |
| Regular Market Time | 1,776,456,001 |
| Regular Market Volume | 672,533 |
| Return On Assets | 0.04242 |
| Return On Equity | 0.061690003 |
| Revenue Growth | 0.003 |
| Revenue Per Share | 5.528 |
| Sand P52 Week Change | 0.36506534 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 258,223,736 |
| Shares Percent Shares Out | 0.0077 |
| Shares Short | 7,018,881 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 7,111,167 |
| Short Name | Grifols, S.A. |
| Short Ratio | 6.26 |
| Source Interval | 15 |
| Symbol | GRFS |
| Target High Price | 12.2 |
| Target Low Price | 10.0 |
| Target Mean Price | 11.1 |
| Target Median Price | 11.1 |
| Total Cash | 849,000,000 |
| Total Cash Per Share | 1.247 |
| Total Debt | 9,642,999,808 |
| Total Revenue | 7,523,999,744 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | 0.64 |
| Trailing P E | 13.671875 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 9.2547 |
| Two Hundred Day Average Change | -0.5046997 |
| Two Hundred Day Average Change Percent | -0.054534424 |
| Type Disp | Equity |
| Volume | 672,533 |
| Website | https://www.grifols.com |
| Zip | 8,174 |